248 related articles for article (PubMed ID: 36934113)
21. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
22. ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.
Fukumoto T; Lin J; Fatkhutdinov N; Liu P; Somasundaram R; Herlyn M; Zhang R; Nishigori C
J Invest Dermatol; 2021 Jun; 141(6):1564-1572.e4. PubMed ID: 33333124
[TBL] [Abstract][Full Text] [Related]
23. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
24. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.
Nebhan CA; Johnson DB
Expert Rev Anticancer Ther; 2020 Feb; 20(2):137-145. PubMed ID: 31997676
[No Abstract] [Full Text] [Related]
25. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Ressler JM; Tomasich E; Hatziioannou T; Ringl H; Heller G; Silmbrod R; Gottmann L; Starzer AM; Zila N; Tschandl P; Hoeller C; Preusser M; Berghoff AS
Target Oncol; 2024 Mar; 19(2):263-275. PubMed ID: 38401029
[TBL] [Abstract][Full Text] [Related]
26. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
27. Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?
Haugh A; Daud A
Cancer Immunol Res; 2023 Jul; 11(7):864. PubMed ID: 37262325
[TBL] [Abstract][Full Text] [Related]
28. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
Sheng Y; Tong L; Geyu L
Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
[TBL] [Abstract][Full Text] [Related]
29. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
[TBL] [Abstract][Full Text] [Related]
30. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
31. Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report.
de Joode K; Veenbergen S; Kransse C; Kortleve D; Debets R; Mathijssen RHJ; Joosse A; Schreurs MWJ; Van der Veldt AAM
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36750254
[TBL] [Abstract][Full Text] [Related]
32. Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma.
Rosner S; Agrawal Y; Sun DQ; Aygun N; Schollenberger MD; Lipson E; Naidoo J
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335030
[TBL] [Abstract][Full Text] [Related]
33. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.
Motti ML; Minopoli M; Di Carluccio G; Ascierto PA; Carriero MV
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604720
[TBL] [Abstract][Full Text] [Related]
34. Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
Lentz RW; Colton MD; Mitra SS; Messersmith WA
Mol Cancer Ther; 2021 Jun; 20(6):961-974. PubMed ID: 33850005
[TBL] [Abstract][Full Text] [Related]
35. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.
Yoshihama S; Cho SX; Yeung J; Pan X; Lizee G; Konganti K; Johnson VE; Kobayashi KS
Sci Rep; 2021 Feb; 11(1):3258. PubMed ID: 33547395
[TBL] [Abstract][Full Text] [Related]
36. The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies.
Varghese S; Pramanik S; Williams LJ; Hodges HR; Hudgens CW; Fischer GM; Luo CK; Knighton B; Tan L; Lorenzi PL; Mackinnon AL; McQuade JL; Hailemichael Y; Roszik J; Peng W; Vashisht Gopal YN
Mol Cancer Ther; 2021 Mar; 20(3):500-511. PubMed ID: 33361272
[TBL] [Abstract][Full Text] [Related]
37. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
38. Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.
Mao R; Yang F; Zhang T; Li J
Front Immunol; 2021; 12():756282. PubMed ID: 35003069
[TBL] [Abstract][Full Text] [Related]
39. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.
Miao YR; Liu CJ; Hu H; Yang M; Guo AY
Cells; 2022 Sep; 11(18):. PubMed ID: 36139377
[TBL] [Abstract][Full Text] [Related]
40. PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models.
Wong CW; Evangelou C; Sefton KN; Leshem R; Zhang W; Gopalan V; Chattrakarn S; Fernandez Carro ML; Uzuner E; Mole H; Wilcock DJ; Smith MP; Sergiou K; Telfer BA; Isaac DT; Liu C; Perl NR; Marie K; Lorigan P; Williams KJ; Rao PE; Nagaraju RT; Niepel M; Hurlstone AFL
Nat Commun; 2023 Sep; 14(1):5983. PubMed ID: 37752135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
